[
    [
        {
            "time": "2021-03-15",
            "original_text": "Eli Lilly And Incyte’s Baricitinib Fails To Meet Endpoint In Phase 3 COVID-19 Trial",
            "features": {
                "keywords": [
                    "Baricitinib",
                    "Phase 3",
                    "COVID-19",
                    "fails",
                    "trial"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly And Incyte’s Baricitinib Fails To Meet Endpoint In Phase 3 COVID-19 Trial",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-04-16",
            "original_text": "Lilly (LLY) to End Solo Bamlanivimab Use, Back COVID-19 Combo",
            "features": {
                "keywords": [
                    "Lilly",
                    "Bamlanivimab",
                    "End",
                    "Solo Use",
                    "COVID-19",
                    "Combo"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Lilly (LLY) to End Solo Bamlanivimab Use, Back COVID-19 Combo",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]